Koichi Goto
Overview
Explore the profile of Koichi Goto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
331
Citations
7243
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uehara Y, Izumi H, Kobayashi I, Matsumoto S, Hosomi Y, Okuno T, et al.
Lung Cancer
. 2025 Mar;
202:108479.
PMID: 40088581
Background: EGFR exon 19 insertions (EGFRex19ins) are rare EGFR mutations. Their clinical-genomic characteristics and outcomes with EGFR-tyrosine kinase inhibitors (TKIs) remain uncertain. Methods: We evaluated the clinical-genomic characteristics and outcomes...
2.
Uehara Y, Izumi H, Taki T, Sakai T, Udagawa H, Sugiyama E, et al.
JTO Clin Res Rep
. 2025 Feb;
6(3):100779.
PMID: 40007550
Introduction: Resistance to EGFR tyrosine kinase inhibitors is influenced by tumor-intrinsic and -extrinsic factors. We investigated the impact of tumor cell histology and tumor microenvironment on the efficacy of osimertinib....
3.
Gautschi O, Park K, Solomon B, Tomasini P, Loong H, De Braud F, et al.
J Clin Oncol
. 2025 Feb;
:JCO2402076.
PMID: 39983053
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up, we report the final efficacy and safety...
4.
Schram A, Goto K, Kim D, Macarulla T, Hollebecque A, OReilly E, et al.
N Engl J Med
. 2025 Feb;
392(6):566-576.
PMID: 39908431
Background: Neuregulin 1 () fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 and...
5.
Qi Z, Tokuhiro S, Odegaard J, Wienke S, Karnoub M, Feng W, et al.
J Mol Diagn
. 2025 Jan;
27(2):119-129.
PMID: 39880580
This study demonstrates the analytical and clinical validity of the approved (United States and Japan) plasma-based Guardant360 companion diagnostic (CDx) test for selecting patients with human epidermal growth factor receptor...
6.
Spira A, Cho B, Felip E, Garon E, Goto K, Johnson M, et al.
Lung Cancer
. 2025 Jan;
199:108066.
PMID: 39764938
No abstract available.
7.
Besse B, Goto K, Wang Y, Lee S, Marmarelis M, Ohe Y, et al.
J Thorac Oncol
. 2025 Jan;
PMID: 39755170
Introduction: Treatment options for patients with EGFR-mutated NSCLC with disease progression on or after osimertinib and platinum-based chemotherapy are limited. Methods: CHRYSALIS-2 cohort A evaluated amivantamab plus lazertinib in patients...
8.
Ito Y, Zenke Y, Sakai T, Shibata Y, Izumi H, Nosaki K, et al.
Future Oncol
. 2024 Dec;
21(4):473-481.
PMID: 39734266
Aims: This study aimed at developing a scoring system (EAST score) to predict recurrence after chemoradiotherapy in limited-stage small-cell lung cancer (LS-SCLC). Patients & Methods: Treatment-naïve LS-SCLC patients receiving concurrent...
9.
Blechter B, Hsiung C, Wang X, Zhang H, Seow W, Shi J, et al.
J Thorac Oncol
. 2024 Nov;
PMID: 39581378
We assessed the association between a genome-wide polygenic risk score (PRS) developed for lung adenocarcinoma (LUAD) risk and mutation on the EGFR gene in 998 East Asian never-smoking female LUAD...
10.
Matsumoto Y, Umemura S, Okizaki A, Fujisawa D, Yamaguchi T, Oyamada S, et al.
Cancer Med
. 2024 Nov;
13(22):e70325.
PMID: 39556485
Background: We aimed to examine the effectiveness of a nurse-led, screening-triggered early specialized palliative care intervention program for patients with advanced lung cancer. Methods: Patients with advanced lung cancer who...